Choon-Peng Ng, ImmunoScape CEO
TCR upstart gets fresh funding as it looks to charge toward the clinic
While several companies have been finding success in the TCR-T cell therapy space — with Intellia having its treatment accepted by the FDA last year — another company is using machine learning to get in on the action and find a candidate to bring toward the clinic.
ImmunoScape, a biotech based in Singapore and California, has raised $14 million in a fresh round of financing. The company itself was founded in 2016 as a spinout from the Singapore-based Agency for Science, Technology and Research, setting up its US operations in San Diego in 2020.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters